Facing a patent cliff and erosion from generic drugs, many pharmaceutical companies are relying on partnerships with biotech companies for innovation and development.
Shifting dynamics are now prompting some biotechs to seek more balanced deals than in the past, sharing rewards as well as risks, according to an article on the BioWorld Today website.
?Pharmas at the moment are cash-rich and molecule-poor,? says Nick Davies, co-author of a report on the pharmaceutical industry from global consulting firm PwC. That?s why they?re looking to biotechs as development engines.